Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00007890-197909000-00016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.
Leukemia
January 2025
Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Off-label hypomethylating agents and venetoclax (HMA/VEN) are often used for relapsed and refractory (R/R) AML patients. However, predictors of outcome are elusive. The objective of the current retrospective observational multicenter study of 240 adult patients (median age 68.
View Article and Find Full Text PDF[Disseminated toxoplasmosis after cord blood transplantation diagnosed at autopsy].
Rinsho Ketsueki
January 2025
Department of Hematology and Oncology, Tokai University School of Medicine.
A 54-year-old woman underwent cord blood transplantation in second remission of acute myeloid leukemia. She tested positive for anti-toxoplasma IgG antibody before transplantation. After neutrophil engraftment, she complained of foggy vision, but brain MRI showed no abnormality.
View Article and Find Full Text PDFA 66-year-old woman was diagnosed with chronic lymphocytic leukemia (CLL) due to the finding of leukocytosis and started acalabrutinib and obinutuzumab (AO) therapy. After three cycles of AO therapy, she developed severe pancytopenia with hypoplastic bone marrow and was diagnosed with fulminant aplastic anemia (AA) due to neutropenia with no response to granulocyte colony-stimulating factor. One month after the onset of AA, she received HLA-haploidentical allogeneic hematopoietic stem cell transplantation (haplo-SCT) from a daughter using FluMelTBI (fludarabine 180 mg/m, melphalan 80 mg/m, total body irradiation 4 Gy) as the conditioning regimen and tacrolimus, mycophenolate mofetil, and post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis.
View Article and Find Full Text PDFOutcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.
ESMO Open
January 2025
Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy; Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy. Electronic address:
Background: Daratumumab-refractory multiple myeloma (Dara-R MM) presents a significant treatment challenge. This study aimed to evaluate the efficacy and survival outcomes of elotuzumab, pomalidomide, and dexamethasone (EloPd) in a large, real-world cohort of patients with Dara-R MM, with particular focus on progression-free survival (PFS) and overall survival (OS).
Materials And Methods: This retrospective analysis included 247 Dara-R MM patients treated with EloPd.
Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
J Clin Oncol
January 2025
Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN.
Purpose: Melanoma as a subsequent malignant neoplasm has been described among childhood cancer survivors; however, the risk factors and long-term survival are not well understood.
Methods: We assessed incidence, risk factors, and outcomes for melanoma among participants in the Childhood Cancer Survivor Study cohort. Cumulative incidence and standardized incidence ratios (SIRs) were calculated, and multivariable Cox models were used to determine hazard ratios (HRs) and associated 95% CI for melanoma risk factors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!